1.
Nieminen
MS
,
Cleland
JG
,
Eha
J
,
Belenkov
Y
,
Kivikko
M
,
Poder
P
, et al
.
Oral levosimendan in patients with severe chronic heart failure: the PERSIST study
.
Eur J Heart Fail
.
2008
;
10
(
12
):
1246
54
.
2.
Mathew
R
,
Di Santo
P
,
Jung
RG
,
Marbach
JA
,
Hutson
J
,
Simard
T
, et al
.
Milrinone as compared with dobutamine in the treatment of cardiogenic shock
.
N Engl J Med
.
2021
;
385
(
6
):
516
25
.
3.
Gustafsson
F
,
Damman
K
,
Nalbantgil
S
,
Van Laake
LW
,
Tops
LF
,
Thum
T
, et al
.
Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology
.
Eur J Heart Fail
.
2023
;
25
(
4
):
457
68
.
4.
O'Connor
CM
,
Gattis
WA
,
Uretsky
BF
,
Adams
KF
Jr
,
McNulty
SE
,
Grossman
SH
, et al
.
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)
.
Am Heart J
.
1999
;
138
(
1 Pt 1
):
78
86
.
5.
McDonagh
TA
,
Metra
M
,
Adamo
M
,
Gardner
RS
,
Baumbach
A
,
Bohm
M
, et al
.
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC
.
Eur Heart J
.
2021
;
42
(
48
):
4901
.
6.
Hansen
BL
,
Kristensen
SL
,
Gustafsson
F
.
Use of inotropic agents in advanced heart failure: pros and cons
.
Cardiology
.
2024
.
7.
Teerlink
JR
,
Diaz
R
,
Felker
GM
,
McMurray
JJV
,
Metra
M
,
Solomon
SD
, et al
.
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
.
N Engl J Med
.
2021
;
384
(
2
):
105
16
.
You do not currently have access to this content.